Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals

被引:6
作者
van Uum, SHM
Houben, AJHM
Hermus, ARMM
Kroon, AA
Walker, BR
Sweep, CGJ
Smits, P
de Leeuw, PW
Lenders, JWM
机构
[1] Univ Nijmegen, Med Ctr, Div Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Med Ctr, Div Endocrine, Dept Med, NL-6500 HB Nijmegen, Netherlands
[3] State Univ Limburg Hosp, Dept Med, CARIM, NL-6201 BX Maastricht, Netherlands
[4] Univ Edinburgh, Western Gen Hosp, Dept Med Sci, Edinburgh, Midlothian, Scotland
[5] Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands
[6] Univ Nijmegen, Med Ctr, Dept Pharmacol, NL-6500 HB Nijmegen, Netherlands
关键词
renal blood flow; 11 beta-hydroxysteroid dehydrogenase; cortisol; cortisone; glycyrrhetinic acid; hypertension;
D O I
10.1097/00004872-200211000-00028
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Cortisol is known to increase blood pressure. One possible mechanism is the reported increase in renal vascular resistance (RVR). It is unknown whether this is due to a direct effect of cortisol on the kidneys. Objective To study the effect of infusion of cortisol directly into the renal artery on renal blood flow (RBF) and on renal 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-mediated conversion of cortisol to cortisone in patients with primary hypertension. Design and methods Twenty-seven patients with primary hypertension participated in this study. Fifteen received placebo and 12 received glycyrrhetinic acid (GRA; 500 mg) orally 2.5 h before the study. After a 10 min infusion of 5% glucose, cortisol was infused in stepwise increasing doses (0.625,1.25 and 2.5 mug/kg per min), for 10 min each dose. At the end of each infusion step, RBF was measured using the xenon-133 washout technique. Plasma samples from the femoral artery and renal vein were taken for measurement of cortisol and cortisone. Urine was collected for measurement of steroid concentrations for 6 h on the day before the infusion and for 6 h after the infusion. Results After placebo or GRA, cortisol infusion did not change RVR, RBF or blood pressure. RVR values were 0.72 (0.45-0.89) mmHg/ml per min per 100 ml tissue [median (first and third quartiles)] and 0.71 (0.64-0.91) mmHg/ml per min per 100 ml tissue during infusion of 5% glucose and infusion of the highest dose of cortisol, respectively (P = NS). Cortisol infusion increased the venous-arterial difference in plasma cortisone concentration across the kidney from 76 (40-115) nmol/l to 138 (100-186) nmol/l (P < 0.05) and increased the cortisol: cortisone ratios in the renal vein and in urine (both P < 0.05). As compared with placebo, administration of GRA increased the cortisol: cortisone ratios in peripheral and renal veins and in the urine. Conclusion Acute infusion of cortisol in high doses directly into the renal artery in patients with primary hypertension did not affect RBF or RVR. Infusion of cortisol resulted in increased cortisol -cortisone conversion by renal 11 P-HSD2, but the concurrent increase in renal and urinary cortisol: cortisone ratio suggests a relative insufficiency of renal 11 P-HSD2 activity as a result of enzyme saturation. This may enhance mineralocorticoid receptor stimulation by cortisol. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:2275 / 2283
页数:9
相关论文
共 29 条
  • [1] Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries
    Alzamora, R
    Michea, L
    Marusic, ET
    [J]. HYPERTENSION, 2000, 35 (05) : 1099 - 1104
  • [2] CONNELL JMC, 1987, J HYPERTENS, V5, P425
  • [3] Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide
    De Matteo, R
    May, CN
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1997, 273 (06) : R1972 - R1979
  • [4] Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep
    De Matteo, R
    May, CN
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (04) : R1125 - R1131
  • [5] Deinum J, 1999, CLIN CHEM, V45, P847
  • [6] LOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR
    EDWARDS, CRW
    BURT, D
    MCINTYRE, MA
    DEKLOET, ER
    STEWART, PM
    BRETT, L
    SUTANTO, WS
    MONDER, C
    [J]. LANCET, 1988, 2 (8618) : 986 - 989
  • [7] MINERALOCORTICOID ACTION - TARGET TISSUE-SPECIFICITY IS ENZYME, NOT RECEPTOR, MEDIATED
    FUNDER, JW
    PEARCE, PT
    SMITH, R
    SMITH, AI
    [J]. SCIENCE, 1988, 242 (4878) : 583 - 585
  • [8] EFFECT OF ADRENAL SUPPRESSION WITH DEXAMETHASONE IN ESSENTIAL HYPERTENSION
    HAMILTON, BP
    ZADIK, Z
    EDWIN, CM
    HAMILTON, JH
    KOWARSKI, AA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 48 (05) : 848 - 853
  • [9] RENAL CAPTURE AND OXIDATION OF CORTISOL IN MAN
    HELLMAN, L
    NAKADA, F
    ZUMOFF, B
    FUKUSHIMA, D
    BRADLOW, HL
    GALLAGHER, TF
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1971, 33 (01) : 52 - +
  • [10] ARE THE HYPOKALEMIA AND HYPERTENSION IN CUSHINGS-DISEASE CAUSED BY APPARENT MINERALOCORTICOID EXCESS
    HERMUS, A
    HOBMA, S
    PIETERS, G
    VANDECALSEYDE, J
    SMALS, A
    KLOPPENBORG, P
    [J]. HORMONE AND METABOLIC RESEARCH, 1991, 23 (11) : 572 - 573